The influence of HIV-1 subtype in the response to therapeutic dendritic cell vaccine

Open AIDS Journal

Volumn 6, Issue 1, 2012, Pages 289-292

  Ferreira, Valéria ^a   Moura, Patrícia ^b   Crovella, Sergio ^a   Diaz, Ricardo Sobhie ^c   Filho, Adauto Castelo ^c   Ximenes, Ricardo ^c   Arraes, Luiz Cláudio ^c  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dendritic cells; HIV 1 subtype; Immunotherapy; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VACCINATION; VIRAL GENETICS; VIRUS FORMS; VIRUS LOAD;

EID: 84885361809     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601206010289     Document Type: Article

References (19)

1. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003; 101: 4505-11.
2. Beuria P, Chen H, Timoney M, Sperber K. Impaired accessory cell function in a human dendritic cell line after human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12: 453-64.
3. Salerno-Goncalves R, Lu W, Andrieu JM. Quantitative analysis of the antiviral activity of CD8(+) T cells from human immunodeficiency virus-positive asymptomatic patients with different rates of CD4(+) T-cell decrease. J Virol 2000; 74: 6648-51.
4. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10: 1359-65.
5. Soares MA, De Oliveira T, Brindeiro RM, et al. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS 2003; 17: 11-21.
6. De Sa Filho DJ, Sucupira MC, Caseiro MM, Sabino EC, Diaz RS, Janini LM. Identification of two HIV type 1 circulating recombinant forms in Brazil. AIDS Res Hum Retroviruses 2006; 22: 1-13.
7. Leal E ML, Janini LM, Diaz RS. Evolutionary dynamics of HIV-1 BF and CB recombinants and its parental counterparts in South America. Retrovirology 2008; 1: 1-14.
8. Sanabani S, Neto WK, de Sa Filho DJ, et al. Full-length genome analysis of human immunodeficiency virus type 1 subtype C in Brazil. AIDS Res Hum Retroviruses 2006; 22: 171-6.
9. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980; 16: 111-20.
10. Apetrei C, Loussert-Ajaka I, Descamps D, et al. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS 1996; 10: F57-60.
11. Burgisser P, Vernazza P, Flepp M, et al. Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2000; 23: 138-44.
12. Kaleebu P, Ross A, Morgan D, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15: 293-9.
13. Kanki PJ, Hamel DJ, Sankale JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179: 68-73.
14. De Cock KM, Brun-Vezinet F. Epidemiology of HIV-2 infection. AIDS 1989; 3(Suppl 1): S89-95.
15. Matheron S, Mendoza-Sassi G, Simon F, Olivares R, Coulaud JP, Brun-Vezinet F. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997; 11: 934-6.
16. Fusuma EE, Caruso SC, Lopez DF, et al. Duplication of perikappaB and NF-kappab sites of the first human immunodeficiency virus type 2 (HIV-2) transmission in Brazil. AIDS Res Hum Retroviruses 2005; 21: 965-70.
17. Accetturi CA, Pardini R, Novaes Pinto GH, Turcato G Jr, Lewi DS, Diaz RS. Effects of CCR5 genetic polymorphism and HIV-1 subtype in antiretroviral response in Brazilian HIV-1-infected patients. J Acquir Immune Defic Syndr 2000; 24: 399-400.
18. Calazans A, Brindeiro R, Brindeiro P, et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005; 191: 1961-70.
19. Diaz RS, Vasconcelos L, Hayden RL, et al. Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil. J Acquir Immune Defic Syndr 2008; 47: 399-401.